Director, Histology and Histochemistry Group
- Employer
- 4D Molecular Therapeutics
- Location
- Emeryville, CA, United States
- Start date
- Oct 23, 2019
View more
- Discipline
- Science/R&D, Biology, Cell Biology, Research, Computational Science
- Required Education
- Associate Degree
- Position Type
- Full time
Job Details
In order to streamline data generation, 4DMT is looking to hire an immunohistochemistry (IHC) expert to provide analysis of data, generate new protocols, manage in-house work, identify work to be outsourced and monitor such work. This role will be an independent function that reports to the Chief Medical Officer/Head of Translational Medicine. This function will be involved with multiple programs, in research to late stage preclinical programs. The data generated will inform doses for IND-enabling studies and require high level of organization and ability to write reports that will be part of IND packages.
MAJOR RESPONSIBILITIES:
- Propose and manage internal and outsourced projects with costs, timing, and quality rationale
- Develop and direct IHC protocols including tissue fixation, trimming, embedding, sectioning, staining, and analysis
- IHC assay development/validation and management of assay transfer to CRO for implementation in preclinical and clinical trials
- Direct associate or CRO on H&E staining, immunofluorescence, or colorimetric staining
- Develop in house or outsourced imaging (including high-throughput imaging)
- Develop in house or outsourced image quantitative and/or semi-quantitative analyses
- Identify outsourced resources for histopathology assessments of a multitude of tissue types
- Review data and generate presentations for executive committee
- Work with PM to develop timelines and to understand corporate goals to prioritize data generation
- Scientific writing in support of non-clinical IHC IND data package
KNOWLEDGE AND SKILLS:
- A BS or MS in a biological science
- 7-10+ years of industry and/or academic experience performing and managing histology activities
- Strong IHC experience including development of protocols
- Ability to lead a highly focused scientific team to meet timelines and deliverables
- Ability to work in and prioritize projects across a matrixed, cross-functional organization
- Ability to implement new techniques in house or with a CRO
- Must have experience working with CROs and to be able to communicate clearly protocol requirements
- Confident and respectful when interacting with all levels of management
- Strong interpersonal skills and professional demeanor
- Travel Time: 10%
Company
4DMT is a gene therapy company with a transformative discovery platform --Therapeutic Vector Evolution --that enables our “disease first” approach to product discovery and development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the underlying disease.
At 4DMT we are creating and developing optimized “biopharmaceutical grade” AAV vectors that will allow us uniquely to unlock the full potential of gene therapy. Our customized and proprietary AAV vectors are each designed, according to a 4DMT Target Vector Profile, to deliver genes to specific cells and tissues in the body to eradicate both rare and large market diseases.
While AAV gene therapy pioneers are making great strides with the first wave of products, hurdles still exist with the use of conventional vectors. The most commonly used AAV capsids (e.g., AAV2, 5, 8 and 9) were identified either 1) as contaminants in lab stocks of adenovirus, or 2) through monkey tissue processing. Therefore, these conventional vectors are not targeted specifically to any tissue in the body. This can lead to inefficient and non-specific delivery, thus requiring extremely high doses and potentially resulting in toxicities (including inflammation), high manufacturing burdens and suboptimal efficacy. In addition, suboptimal routes of delivery can be required for delivery to the right tissues (e.g., subretinal delivery to the retina). Finally, pre-existing neutralizing antibodies in many patients can limit efficacy, clinical trial enrollment and market sizes. 4DMT Innovation empowers us to create new and improved next generation AAV capsids to allow targeted delivery of our products by the optimal clinical route of administration.
At 4DMT we use our robust discovery platform, termed “Therapeutic Vector Evolution,” to create customized and proprietary gene delivery vehicles (novel AAV vectors) to deliver genes to specific tissues and cells in the body by the optimal route of administration. We use the power of evolution to create and refine these optimized vectors through genetic diversification and then natural selection in vivo.
4D Purpose Statement: Boldly Innovating to Unlock the Full Potential of Gene Therapy for Countless Patients
GUIDING PRINCIPLES
- Dare to Cure - Patients are waiting. Create big dreams for patients and take calculated risks to achieve them
- Break Boundaries - Question the status quo and innovate beyond conventional approaches
- Beyond Yourself - It's about patients, their families, our team, our families. We strengthen each other.
- Prepare and Execute Relentlessly - Start with the end in mind, over-prepare and make contingency plans to your contingency plans
We invite all of you who share our passion and vision in creating the ultimate gene therapy products to cure genetic and rare diseases in children and adults. We seek the best people in the industry who identify with our mission and innovative results-driven approach. We offer an inspiring and collaborative environment that encourages individual contributions, recognizes performance in multiple ways, offers generous benefits and provides challenging opportunities for career development.
- Website
- http://www.4dmoleculartherapeutics.com/
- Phone
- 510-505-2680
- Location
-
5858 Horton St. Suite 455
Emeryville
California
94608
United States
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert